Jun Chung, PhD

Jun Chung, PhD

Associate Professor, Department of Pathology

Office: (631) 469-7176

Fax: (631) 444-3424

Email: Jun.Chung@stonybrookmedicine.edu

Address:
Basic Sciences Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691

Education

BS, Biochemistry, Yonsei University, Seoul, Korea
MS, Genetics and Cell Biology, University of Minnesota, Minneapolis, MN
PhD, Molecular Cell Biology, Washington University School of Medicine, St. Louis, MO
Postdoc: Harvard Medical School

Research Interests

My research is focused on development of therapeutics and diagnostics for breast cancers. Specific emphasis is on the molecular signature that makes Triple Negative Breast Cancers (TNBCs) aggressive so that TNBC specific biomarker and therapeutic intervention can be developed. TNBCs represent most aggressive subtype of breast cancers without effective treatment options. There are 3 major projects available for students and postdocs. 

  1. Therapeutic targeting of tumor suppressing micro-RNAs: Our lab is interested in characterizing tumor suppressing micro-RNAs whose expression is suppressed in metastatic breast cancers such as TNBCs. Current projects involve chemical modification of these tumor suppressing micro-RNAs to enhance their therapeutic efficacy and delivery.
  2. Cancer derived exosomes as early stage biomarkers: Exosome specific contents such as proteins, DNAs, and micro-RNAs are being analyzed for liquid biopsy early-stage marker for breast and colon cancers. We are analyzing exosomes from plasma of various stages of caner patients’ blood samples.
  3. Therapeutic targeting of Epithelial to Mesenchymal transition (EMT) to reverse treatment resistance in TNBCs: Various aspects of EMT such as cell motility persistence, invasion and 3D growth are studied using live cell imaging confocal microscopy. Elucidation of mechanisms that enhance EMT will lead to therapeutic intervention that reverses chemoresistance in TNBCs.
  • 1994-1999
    Research Assistant, Molecular Cell Biology Program, Washington University School of Medicine, St. Louis, MO
  • 2000-2005
    Research Associate, Department of Pathology, Harvard Medical School, Boston, MA
  • 2005
    Postdoc, Department of Pathology, Harvard Medical School, Boston, MA
  • 2007-present
    Consultant, Tumor Biology, Biogen IDEC, Inc., San Diego, CA
  • 2005-2013
    Member, Graduate Faculty (Biochemistry & Molecular Biology), Louisiana State University, Shreveport, LA
  • 2006-2013
    Member, Breast Cancer Focus Group, Louisiana State University Health Sciences Center, Shreveport, LA
  • 2005-2013
    Member, Invasion and Metastasis Group, Louisiana State University Health Sciences Center, Shreveport, LA
  • 2005-2013
    Member, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA
  • 2005-2011
    Assistant Professor, Department of Biochemistry, Louisiana State University Health Sciences Center, Shreveport, LA
  • 2011-2013
    Associate Professor w/tenure, Dept. of Biochemistry, Louisiana State University Health Sciences Center, Shreveport, LA
  • 2012-2013
    Director of Breast Cancer Focus Group in Feist Weiler Cancer Center, Shreveport, LA
  • 2013-2015
    Oklahoma TSET Cancer Research Scholar, Stephen Cancer Center, University of Oklahoma Health Sciences Center
  • 2013-2015
    Associate Professor, Department of Physiology, University of Oklahoma Health Sciences Center
  • 2015-present
    Associate Professor, Department of Pathology, Stony Brook Medicine
  • Chung J, Gao AG, Frazier WA.  Thrombospondin acts via integrin associated protein to activate the platelet integrin aIIbb3. J Biol Chem 1997;272:14740-46
  • Chung J, Wang XQ, Lindberg FP, Frazier WA. Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in a2b1-mediated platelet activation. Blood 1999;94:642-48
  • Green JM, Zhelesnyak A, Chung J, Lindberg FP, Sarfati M, Frazier WA, Brown EJ. Role of Cholesterol in formation and function of a signaling complex involving avb3, integrin associated protein (CD47), and heterotrimeric G proteins. J Cell Biol 1999 146: 673-82
  • Bachelder RE, Crago A, Chung J, Wendt M, Shaw L, Robinson G, and Mercurio AM. VEGF is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61: 5736-40
  • Chung J, Bachelder RE, Lipscomb E, Shaw LM, and Mercurio AM. Integrin (a6b4) regulation of eIF-4E  activity and VEGF translation. J Cell Biol 2002, 158:165-174
  • Mercurio AM, Bachelder RE, Bates, RC and Chung J. Autocrine Signaling in Carcinoma: VEGF and the a6b4 Integrin. Semin Cancer Biol 2004, 14: 115-122
  • Chung J* and Mercurio AM. Contribution of the a6 Integrins to Breast Carcinoma Cell Survival and Progression. Mol Cells 2004, 17 (2): 203-209
  • Chung J, Yoon S, Datta K, Bachelder RE and Mercurio AM. Hypoxia induced VEGF transcription and survival is dependent on a6 integrin expression in breast carcinoma cells. Cancer Res 2004, 64: 4711-4716
  • Chung J, Yoon S, Lipscomb E and Mercurio AM. Met and the a6b4 integrin can function independently to promote carcinoma invasion. J Biol Chem 2004, 279: 32287-32293
  • Lui L, Chen L, Chung J and Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008 May, 27:4998-5010
  • Kim HI, Huang H, Cheepala S, Huang S and Chung J*. Curcumin inhibition of integrin (a6b4) dependent breast cancer cell motility and invasion. Cancer Prevention Research 2008, Oct, 1 (5):385-391
  • Kim TH, Kim HI, Soung YH, Shaw LM and Chung J*.Integrin (a6b4) Signal through Src to increase a Metastasis Promoting Factor, S100A4 Expression: Implications to Cancer Cell Invasion. Molecular Cancer Research 2009, Oct 6 7(10)
  • Korneeva NL, Soung YH, Kim HI, Cheng B, Giordano A, Rhoads RE, Gram H, and Chung J*. Mnk kinase regulates integrin (a6b4) dependent translation initiation via alteration of eIF4F integrity Molecular Cancer Research 2010 Oct 21 Vol 8, Issue 12: 1571-1578 (selected as a highlighted article by editors)
  • Soung YH and Chung J*. Curcumin inhibition of functional interaction between integrin a6b4 and epidermal growth factor receptor. Molecular Cancer Therapeutics 2011 May;10(5):883-91
  • Soung YH, Pruitt K, Chung J*. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Scientific Reports. 2014 Jan 24: 4:3846
  • Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X, Barzegar M, Chung J, and Huang S. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget 2015 Jan 23: 1-15
  • Soung YH, Coleman D, Cardelli JA, and Chung J*. Curcumin inhibits DHHC3 activity and palmitoylation of integrin beta4 in breast cancer cells. Plos One 2015 May 4: 10 (5): e0125399
  • Soung YH, Nguyen T, Cao H, Lee J and Chung J*. Emerging roles of exosomes in cancer invasion and metastasis. BMB Reports 2015 Nov 20 (Epub ahead of print)
  • Soung YH, Nguyen T, Cao H, Lee J and Chung J*. Emerging roles of exosomes in cancer invasion and metastasis. BMB Reports 2016 Jan, 49 (1): 18-25
  • Soung YH, Ford S, Zhang V, and Chung J*. Exosomes in cancer diagnostics. Cancers. 2017 Jan 12:9 (1)
  • Soung YH, Kashahp T, Ngyuen T, Yadav G, Chang H,  Landesman Y, and Chung J*. Selective inhibitor of nuclear export (SINE) compounds block migration and proliferation of Triple Negative Breast Cancer cells by restoring expression of ARRDC3. Oncotarget. 2017 May 18;8(32):52935-52947.
  • Soung YH, Ford S, Zhang C, and Chung J*. The role of ARRDC3 in regulating endocytic recycling and extracellular vesicle sorting of integrin beta4 in breast cancer. Cancers. 2018 Dec 11;10(12).
  • Soung YH, H Chung, C Yan, J Ju, and Chung J*. Arrestin domain containing 3 reverses epithelial to mesenchymal transition and chemo-resistance of TNBC cells by up-regulating expression of miR-200b. Cells 2019. July 10; 8 (7).
  • Soung YH, Chung HS, Fesler A, Kim H, Oh ES Ju J, and Chung J*. Therapeutic potentials of    modified miR-489 mimic in Triple Negative Breast Cancer. Cancers 2020. Aug 7;12(8):2209.
  • Soung YH, and Chung J*. Combination treatment strategies to overcome PARP inhibitor resistance. Biomolecules 2023 Oct 3;13(10):1480. PMID: 37892162.
  • Soung YH, Ju J, and Chung J*. Sensitization of Triple-Negative Breast Cancers to PARP Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489. Cells 2024 Jan 8;13(1):49.
  • Chung J*, Xiao S, Gao Y, Soung YH. Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers. Int J Mol Sci. 2024 Aug 9;25(16):8703.

pubmed logo